RU2006142418A - Способ лечения рака - Google Patents
Способ лечения рака Download PDFInfo
- Publication number
- RU2006142418A RU2006142418A RU2006142418/14A RU2006142418A RU2006142418A RU 2006142418 A RU2006142418 A RU 2006142418A RU 2006142418/14 A RU2006142418/14 A RU 2006142418/14A RU 2006142418 A RU2006142418 A RU 2006142418A RU 2006142418 A RU2006142418 A RU 2006142418A
- Authority
- RU
- Russia
- Prior art keywords
- mammal
- administering
- formula
- effective amount
- therapeutically effective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) трастузумаба.2. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) летрозола.3. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) капецитабина.4. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) топотекана.5. Способ лечения рака легких у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) доцетаксела.6. Способ лечения рака легких у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) топотекана.7. Способ лечения колоректального рака у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) топотекана.8. Способ лечения рака молочной железы у млекопитающего, включающий введение указанному млекопитающему терапевтически эффективных количеств1) соединения формулы (I")2) соединения с антиэстрогенной активностью.
Claims (8)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57733704P | 2004-06-04 | 2004-06-04 | |
US60/577,337 | 2004-06-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008150250/14A Division RU2008150250A (ru) | 2004-06-04 | 2008-12-19 | Способ лечения рака |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006142418A true RU2006142418A (ru) | 2008-07-20 |
RU2361589C2 RU2361589C2 (ru) | 2009-07-20 |
Family
ID=35503649
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006142418/14A RU2361589C2 (ru) | 2004-06-04 | 2005-06-03 | Способ лечения рака |
RU2008150250/14A RU2008150250A (ru) | 2004-06-04 | 2008-12-19 | Способ лечения рака |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008150250/14A RU2008150250A (ru) | 2004-06-04 | 2008-12-19 | Способ лечения рака |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090317383A1 (ru) |
EP (1) | EP1765344A4 (ru) |
JP (1) | JP2008501708A (ru) |
KR (1) | KR20070034536A (ru) |
CN (2) | CN101564535A (ru) |
AU (2) | AU2005251769B2 (ru) |
BR (1) | BRPI0511765A (ru) |
CA (1) | CA2569139A1 (ru) |
IL (1) | IL179323A0 (ru) |
MA (1) | MA28901B1 (ru) |
MX (1) | MXPA06013952A (ru) |
NO (1) | NO20066079L (ru) |
RU (2) | RU2361589C2 (ru) |
WO (1) | WO2005120512A2 (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1824492B1 (en) * | 2004-12-17 | 2013-07-10 | SmithKline Beecham (Cork) Limited | Lapatinib for treating breast cancer brain metastases |
WO2007143483A2 (en) * | 2006-06-01 | 2007-12-13 | Smithkline Beecham Corporation | Combination of pazopanib and lapatinib for treating cancer |
CN101594870A (zh) * | 2006-08-22 | 2009-12-02 | 康塞特医药品有限公司 | 4-氨基喹唑啉衍生物及其使用方法 |
KR20090094804A (ko) | 2006-10-06 | 2009-09-08 | 다케다 야쿠힌 고교 가부시키가이샤 | 조합 약물 |
JP2010510990A (ja) * | 2006-11-28 | 2010-04-08 | スミスクライン ビーチャム (コーク) リミテッド | 癌の治療方法 |
CA2675366A1 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
EP2255830A1 (en) | 2008-03-03 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Concomitant drug |
US8252805B2 (en) | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
US8236862B2 (en) | 2009-02-06 | 2012-08-07 | University Of Southern California | Therapeutic compositions comprising monoterpenes |
US8568968B2 (en) | 2009-04-13 | 2013-10-29 | University Of Southern California | EGFR polymorphisms predict gender-related treatment |
US20140302050A1 (en) * | 2011-11-09 | 2014-10-09 | Albert Einstein College Of Medicine Of Yeshiva University | Targeting an amphiregulin-derived cell surface neo-epitope |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
EE200200471A (et) * | 2000-02-28 | 2003-12-15 | Aventis Pharma S.A. | Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks |
JP4102185B2 (ja) * | 2000-06-30 | 2008-06-18 | グラクソ グループ リミテッド | キナゾリンジトシル酸塩化合物 |
JP4458746B2 (ja) * | 2001-01-16 | 2010-04-28 | グラクソ グループ リミテッド | 癌の治療方法 |
PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
US20060204966A1 (en) * | 2003-08-01 | 2006-09-14 | Spector Neil L | Treatment of cancers expressing p95 erbb2 |
US8211030B2 (en) * | 2009-03-26 | 2012-07-03 | The General Electric Company | NIBP target inflation pressure automation using derived SPO2 signals |
-
2005
- 2005-06-03 US US11/569,878 patent/US20090317383A1/en not_active Abandoned
- 2005-06-03 CN CNA2009101415491A patent/CN101564535A/zh active Pending
- 2005-06-03 RU RU2006142418/14A patent/RU2361589C2/ru not_active IP Right Cessation
- 2005-06-03 EP EP05758577A patent/EP1765344A4/en not_active Withdrawn
- 2005-06-03 MX MXPA06013952A patent/MXPA06013952A/es active IP Right Grant
- 2005-06-03 CA CA002569139A patent/CA2569139A1/en not_active Abandoned
- 2005-06-03 KR KR1020067027698A patent/KR20070034536A/ko not_active Application Discontinuation
- 2005-06-03 JP JP2007515618A patent/JP2008501708A/ja active Pending
- 2005-06-03 CN CN200580018262XA patent/CN1984656B/zh active Active
- 2005-06-03 WO PCT/US2005/019568 patent/WO2005120512A2/en active Application Filing
- 2005-06-03 BR BRPI0511765-8A patent/BRPI0511765A/pt not_active IP Right Cessation
- 2005-06-03 AU AU2005251769A patent/AU2005251769B2/en active Active
-
2006
- 2006-11-16 IL IL179323A patent/IL179323A0/en unknown
- 2006-12-25 MA MA29554A patent/MA28901B1/fr unknown
- 2006-12-29 NO NO20066079A patent/NO20066079L/no not_active Application Discontinuation
-
2008
- 2008-10-09 AU AU2008229859A patent/AU2008229859A1/en not_active Abandoned
- 2008-12-19 RU RU2008150250/14A patent/RU2008150250A/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2008150250A (ru) | 2010-06-27 |
US20090317383A1 (en) | 2009-12-24 |
BRPI0511765A (pt) | 2008-01-08 |
AU2005251769A1 (en) | 2005-12-22 |
CN1984656A (zh) | 2007-06-20 |
NO20066079L (no) | 2007-01-12 |
IL179323A0 (en) | 2007-05-15 |
WO2005120512A2 (en) | 2005-12-22 |
RU2361589C2 (ru) | 2009-07-20 |
EP1765344A4 (en) | 2009-12-02 |
JP2008501708A (ja) | 2008-01-24 |
AU2008229859A1 (en) | 2008-10-30 |
CA2569139A1 (en) | 2005-12-22 |
CN101564535A (zh) | 2009-10-28 |
EP1765344A2 (en) | 2007-03-28 |
CN1984656B (zh) | 2010-05-26 |
KR20070034536A (ko) | 2007-03-28 |
MXPA06013952A (es) | 2007-02-08 |
WO2005120512A3 (en) | 2006-04-27 |
MA28901B1 (fr) | 2007-10-01 |
AU2005251769B2 (en) | 2008-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006142418A (ru) | Способ лечения рака | |
RU2342159C2 (ru) | Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела | |
RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
RU2016109811A (ru) | Лечение рака комбинацией антагониста pd-1 и динациклиба | |
RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
RS20050975A (en) | Specific binding agents to hepatocyte growth factor | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
RU2011112948A (ru) | Способы лечения рака с использованием ингибиторов киназ | |
BRPI0418745A (pt) | anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente | |
RU2013147514A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
RU2008141682A (ru) | Лечение раковых заболеваний при помощи комбинации таксанов и 13-дезоксиантрациклинов | |
AR048502A1 (es) | Sinergia terapeutica de compuestos anti-cancer | |
ATE341550T1 (de) | Quinolinyl-pyrrolopyrazole | |
MX2007006043A (es) | Metodo de tratamiento de cancer. | |
TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
HK1073601A1 (en) | Epothilone derivative for the treatment of hepatoma and other cancer diseases | |
RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
MA29266B1 (fr) | Traitement de tumeurs metastatiques | |
WO2010036567A3 (en) | Harmine compounds for promoting bone growth | |
BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
ATE461713T1 (de) | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren | |
RU2014139955A (ru) | Прокаспазная комбинированная терапия при глиобластоме | |
WO2010039920A3 (en) | Boldine compounds for promoting bone growth | |
RU2007126358A (ru) | Новая фармацевтическая композиция, содержащая по меньшей мере одно производное доластатина 10 | |
RU2007143434A (ru) | 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110604 |